Organon, STW Technology Foundation and Radboud University Nijmegen to collaborate on bone, fat and cartilage formation research

22-Feb-2006

NV Organon, STW Technology Foundation (STW) and Radboud University Nijmegen plan to run a joint project designed to shed light on the process of bone, fat and cartilage formation. Organon and STW will be providing financial support for the study, which will be conducted by Radboud University Nijmegen's Department of Cell biology and Applied Biology.

The four years research project is in line with the objectives of each of the partners: Organon pursues the development of medicines for bone diseases, STW implements a program focused on tissue engineering innovations, and Radboud University Nijmegen gets an opportunity to unravel the mechanisms triggering stem cells to develop into bone, fat and cartilage tissue.

According to Dr. Ard Cools, Valorization Manager of the STW, the Foundation's financial support is being provided as part of the Dutch Program for Tissue Engineering.

In addition to providing part of the financial support, Organon will also serve as the technology partner.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Glycotope receives regulatory approval for GlycoExpress Technology and initiates clinical trial with antibody GT-MAB 2.5-GEX

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

AMRI Hires Director of In Vitro Biology in Singapore

Action Pharma reports positive results in a proof of concept phase IB study in obese human volunteers treated with AP1030

Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist - Company Anticipates Initiating Phase 2a Studies by Early 2012

Elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board

Galapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeutics

Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor

RIKEN: Discovery of DNA Silencing Mechanism Reveals How Plants Protect Their Genome

Novasep invests EUR 30 million to build world's largest chromatography plant for the pharmaceutical industry - New plant on its Mourenx, France site to produce a large volume commercial API

Prosensa Announces Progress on Exon Skipping Compounds for the Treatment of Duchenne Muscular Dystrophy - £10m in milestone payments received from GlaxoSmithKline

KINAXO Biotechnologies receives 1 million EUR funding to quantify drug interactions with cellular protein targets